Ionis Pharmaceuticals, Inc. (FRA:ISI)
Germany
· Delayed Price · Currency is EUR 69.82
-0.12 (-0.17%)
At close: Dec 4, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| SPINRAZA Royalties Revenue | 221.90M | 216.10M |
Log In |
Log In |
Log In | Upgrade
|
| WAINUA Royalties Revenue | 43.00M | 20.20M |
Log In |
Log In |
Log In | Upgrade
|
| TEGSEDI and WAYLIVRA Revenue | 36.90M | 34.20M |
Log In |
Log In |
Log In | Upgrade
|
| Commercial Licensing and Other Royalty Revenue | 78.60M | 22.60M |
Log In |
Log In |
Log In | Upgrade
|
| Total Commercial Revenue | 380.40M | 293.10M |
Log In |
Log In |
Log In | Upgrade
|
| Amortization from Upfront Payments Revenue | - | 131.40M |
Log In |
Log In |
Log In | Upgrade
|
| Milestone Payments Revenue | - | 106.40M |
Log In |
Log In |
Log In | Upgrade
|
| R&D License Fees Revenue | - | 71.30M |
Log In |
Log In |
Log In | Upgrade
|
| Other R&D Services Revenue | - | 23.50M |
Log In |
Log In |
Log In | Upgrade
|
| Collaborative Agreement Revenue | 510.00M | 332.60M |
Log In |
Log In |
Log In | Upgrade
|
| Eplontersen Joint Development Revenue | 76.40M | 79.40M |
Log In |
Log In |
Log In | Upgrade
|
| Total R&D Revenue | 586.40M | 412.00M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -629.24M | -432.16M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 966.96M | 705.14M |
Log In |
Log In |
Log In | Upgrade
|